Search - tctmd.com

Displaying 1 - 20 of 25

Sort: Relevancy | Date

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

News Daily News

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

Michael O'Riordan

December 14, 2022

Query Use of Nontraditional Therapies for HF at Every Visit: AHA Statement

News Daily News

Query Use of Nontraditional Therapies for HF at Every Visit: AHA Statement

December 09, 2022

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

News Daily News

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

Michael O'Riordan

December 08, 2022

Sequencing HF Meds? Most Doctors Stick to Old Habits, Survey Says

News Daily News

Sequencing HF Meds? Most Doctors Stick to Old Habits, Survey Says

December 08, 2022

STRONG-HF: Fast Optimal GDMT Cuts Deaths, Hospitalizations in Acute HF

News Daily News

STRONG-HF: Fast Optimal GDMT Cuts Deaths, Hospitalizations in Acute HF

October 17, 2022

COVID Drug Paxlovid Interacts With Widely Used CV Meds: Review

News Daily News

COVID Drug Paxlovid Interacts With Widely Used CV Meds: Review

October 12, 2022

Concerning or Reassuring? Long After COVID-19, CMR Still Yields Clues

News Daily News

Concerning or Reassuring? Long After COVID-19, CMR Still Yields Clues

Michael O'Riordan

October 03, 2022

Exercise Keeps Athletic Heart Supple, Strong, Healthy: JACC Deep Dive

News Daily News

Exercise Keeps Athletic Heart Supple, Strong, Healthy: JACC Deep Dive

Michael O'Riordan

September 09, 2022

Older Adults See Rebound in Rates of HF-Related Death: CDC Data

News Daily News

Older Adults See Rebound in Rates of HF-Related Death: CDC Data

September 09, 2022

AHA Urges More Home-Based Dialysis in Advanced Kidney Failure

News Daily News

AHA Urges More Home-Based Dialysis in Advanced Kidney Failure

Michael O'Riordan

August 18, 2022

Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds

News Daily News

Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds

July 25, 2022

Quadruple Therapy Costs Prohibitive for Many HFrEF Patients

News Daily News

Quadruple Therapy Costs Prohibitive for Many HFrEF Patients

June 21, 2022

SERENADE: No Benefit, Possible Harm With Macitentan in HFpEF and PAH

News Daily News ESC Heart Failure 2022

SERENADE: No Benefit, Possible Harm With Macitentan in HFpEF and PAH

May 22, 2022

The Hunt for Protein Culprits in COVID-19’s Cardiac Complications

News Daily News

The Hunt for Protein Culprits in COVID-19’s Cardiac Complications

Michael O'Riordan

May 06, 2022

DELIVER Trial Scores a Win for Dapagliflozin in HFpEF

News Daily News

DELIVER Trial Scores a Win for Dapagliflozin in HFpEF

May 05, 2022

Frailty Does Not Hinder Dapagliflozin’s HFrEF Impact: DAPA-HF Analysis

News Daily News

Frailty Does Not Hinder Dapagliflozin’s HFrEF Impact: DAPA-HF Analysis

May 03, 2022

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

News Daily News

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

Michael O'Riordan

April 29, 2022

CVD Hospitalizations Spiked in Aftermath of 2020 US Election

News Daily News

CVD Hospitalizations Spiked in Aftermath of 2020 US Election

Michael O'Riordan

April 22, 2022

Underuse of GDMT for Heart Failure Even Worse in Low-Income Countries

News Daily News

Underuse of GDMT for Heart Failure Even Worse in Low-Income Countries

April 20, 2022

Revascularization’s Benefits in HFrEF Linked to Gains in LV Function

News Daily News

Revascularization’s Benefits in HFrEF Linked to Gains in LV Function

April 15, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.